As the global biopharma industry looks toward 2027, cross-border M&A, licensing and partnerships between China and Europe are creating new growth opportunities. Chinese biotech companies are increasingly seeking partners to bring their innovations to international markets, while European pharmaceutical companies look to strengthen their pipelines through access to promising China-originated therapies.

Join our panel of industry experts for practical insights into the evolving dynamics of China-Europe pharmaceutical dealmaking and what it means for the year ahead.

Key topics include:

• Trends and opportunities shaping China-Europe pharma dealmaking in 2027
• Strategies for strengthening deal preparedness and maximizing transaction value
• How European buyers and investors evaluate China-originated assets
• The impact of data readiness, due diligence and regulatory requirements on deal timelines